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Virus  titration  may  constitute  a drawback  in the  development  and  use  of replication-defective  viral
vectors  like Semliki  Forest  virus  (SFV).  The  standardization  and validation  of  a  reverse  transcription  quan-
titative PCR  (qRT-PCR)  method  for SFV  titration  is  presented  here.  The  qRT-PCR  target  is  located  within
the  nsp1  gene  of  the  non-structural  polyprotein  SFV  region  (SFV  RNA),  which  allows  the  strategy  to  be
used  for  several  different  recombinant  SFV  constructs.  Titer  determinations  were  carried  out  by  perform-
ing virus  titration  and  infection  assays  with  SFVs  containing  an  RNA coding  region  for the rabies  virus
glycoprotein  (RVGP)  or green  ﬂuorescent  protein  (GFP).  Results  showed  that the standardized  qRT-PCR
is  applicable  for  different  SFV  constructs,  and  showed  good  reproducibility.  To  evaluate  the  correlation
between  the  amount  of functional  SFV  RNA  in  a  virus  lot  and  its infectivity  in  BHK-21  cell  cultures,  a  tem-
perature  mediated  titer  decrease  was  performed  and  successfully  quantitated  by  qRT-PCR.  When  used
for cell  infection  at the  same  multiplicity  of infection  (MOI),  the  temperature  treated  SFV-RVGP  samples
induced  the same  levels  of  RVGP  expression.  Similarly,  when  different  SFV-GFP  lots  with  different  virus
titers,  as accessed  by  qRT-PCR,  were  used  for  cell  infection  at the  same  MOI,  the cultures  showed  compa-
rable amounts  of  ﬂuorescent  cells.  The  data  demonstrate  a good  correlation  between  the  amount  of  virus
used for infection,  as  measured  by  its SFV  RNA,  and  the  protein  synthesis  in  the cells.  In  conclusion,  the
qRT-PCR  method  developed  here  is accurate  and  enables  the  titration  of replication-defective  SFV  vectors,
an  essential  aid for viral  vector  development  as well  as  for  establishment  of production  bioprocesses.. Introduction
The Semliki Forest virus (SFV) is an enveloped, single-stranded
NA virus of positive polarity belonging to the genus Alphavirus,
amily Togaviridae. The viruses of this family comprise a single
on-segmented RNA molecule, which acts as a messenger RNA
Schlesinger and Schlesinger, 1991). The ﬁnding that the SFV was
ble to infect many cell types with high efﬁciency in gene delivery
nd that the use of a strong viral promoter allowed the ampliﬁca-
ion of heterologous RNA into the host cell led to the development
f the SFV expression vector (Liljeström and Garoff, 1991). For
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this purpose, the cDNA corresponding to its genome was cut
and inserted into two different plasmids. The expression plas-
mid  contains the genes for SFV non-structural proteins (nsp1-4)
and the strong subgenomic SFV 26S promoter located upstream
of a polycloning site. The helper plasmid contains the genes for
the structural proteins (Liljeström and Garoff, 1991; Smerdou and
Liljeström, 1999). In order to obtain SFV particles, both plasmids are
linearized and transcribed in vitro in expression and helper RNAs.
After the electroporation of the RNAs in mammalian cells, infec-
tious but non-replicative virus particles are formed, which can be
collected from the supernatant (for review see Lundstrom et al.,
2001; Rayner et al., 2002). These particles can be used for infect-
ing several cell types in vitro or for in vivo gene delivery. Infected
cells can then translate the heterologous RNA and synthesize the
recombinant protein. In a previous study, an SFV vector carrying
the rabies virus glycoprotein (SFV-RVGP) was constructed. Upon
baby hamster kidney (BHK-21) cell infection with SFV-RVGP, RVGP
mRNA ampliﬁcation took place and high levels of RVGP could be
produced (Benmaamar et al., 2009).
An essential step in using recombinant SFV particles is the virus
titration. Traditional methods for assessing cytopathic effects in
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laque assays are often used for the titration of replicative wild
r modiﬁed strains of SFV (Liljestrom et al., 1991; Zusinaite et al.,
007), but these methods are not applicable to non-replicative SFV
ectors, which do not develop plaques. The titration of replication-
eﬁcient SFV vectors has traditionally been accomplished by the
se of methods such as virus infection of plated cells with subse-
uent detection by immunoﬂuorescence using primary antibodies
gainst the protein of interest (Karlsson and Liljestrom, 2003;
ubby et al., 2007) or against the viral replicase (Klimpi et al., 2001),
r even using a reporter gene like green ﬂuorescent protein (GFP) or
-galactosidase (Ni et al., 2005; Zusinaite et al., 2007; Lundstrom,
012). The viral titration can also be performed by dot-blotting
echnique, using radioactively labeled DNA probes (Wahlfors and
organ, 2002). Nevertheless, these methods are time-consuming
nd often not sensitive enough. It is clear that the titration of SFV
ectors still lacks a simple and sensitive technique for an accurate
valuation of the system. A similar demand led to the standardiza-
ion of a qPCR approach for baculovirus titration (Lo and Chao, 2004;
itchman et al., 2007). The qRT-PCR technique is a good alternative
or the titration of SFV vector particles since the diffusion of qRT-
CR technology and prior knowledge about its use in viral titration
rovide considerable support for this approach (Rohr et al., 2002;
itchman et al., 2007; Morsy El-Senousy et al., 2007; Zhang et al.,
008; Zhao et al., 2007).
This study presents the standardization of a method for qRT-
CR titration of non-replicative SFV particles. The method proposed
ere could be applicable to virtually any non-replicative SFV parti-
les since the target for ampliﬁcation is a conserved region of the
ene coding for the nonstructural protein 1 (nsp1). Results of using
ifferent SFV constructs show that qRT-PCR is a suitable method for
FV titration since there is a good correlation between the amount
f SFV containing RNA used for cell infection, the amount of infected
ells, and the production of the recombinant protein.
. Materials and methods
.1. SFV vectors
Different recombinant SFV vectors were obtained by cloning
he gene of interest under the control of the strong subgenomic
romoter, SFV 26S, into the pSFVgen2C plasmid, which code for
on-structural SFV proteins as already described (Karlsson and
iljestrom, 2003; Benmaamar et al., 2009). SFV vectors carrying
enes coding for membrane proteins were used: SFV-RVGP, SFV-
elatonin A1 receptor (Mta-1), SFV-modiﬁed adenosine receptor
Ala-80) and SFV-adenosine receptor A2A (20A2). An SFV-GFP vec-
or expressing cytoplasmic GFP was also used. For obtaining SFV
articles, the genes coding for structural proteins were supplied
y SFV-Helper2 plasmid (Berglund et al., 1993). Brieﬂy, helper and
ifferent expression plasmids were linearized using Spe I and Nru
 restriction enzymes, respectively. Linearized plasmids were tran-
cribed in vitro using SP6 RNA polymerase and the MAXIScript®
P6 kit (Life Technologies, Carlsbad, USA) at 40 ◦C for 2 h. RNA
as then quantitated by ﬂuorimetry using the Quant-itTM RNA
ssay kit (Life Technologies, Eugene, USA). Expression and helper
NAs were used for co-transfect of BHK-21 cells by electropora-
ion. After 24 h recombinant SFV particles were harvested from
upernatant. Before utilization, SFV particles were activated with
-chemotrypsin 0.5 mg/mL  (Sigma–Aldrich, Saint Louis, USA) fol-
owed by enzymatic inactivation with aprotinin 1 mg/mL  (Thermo
isher Scientiﬁc, Rockford, USA). Activated SFV particles were
itrated and used for BHK-21 infection. All virus stocks were main-
ained at −80 ◦C until the moment of activation and utilization.
lternatively, activated SFV-RVGP aliquots were submitted to tem-
eratures of 24 ◦C or 37 ◦C for 1 h or 3 h and then titrated and utilized
or infection.l Methods 193 (2013) 647– 652
2.2. RNA extraction from SFV samples
RNA extraction from SFV samples was  performed using the
RNeasy kit (Qiagen, Maryland, USA), following the manufacturer’s
instructions. First, three SFV-RVGP sample volumes were assayed
(50 L, 100 L, and 200 L) to determinate the best sample size,
based on the amount of RNA required for analysis. The best qRT-
PCR ampliﬁcation performance was found using 100 L. As the
amount of total RNA in any SFV sample was below the limit of
quantitation of our available quantitation methodologies, the RNA
recovery after extraction was evaluated by the introduction of 3 g
yeast tRNA (Life Technologies, Carlsbad, USA) in each SFV sample.
After the extraction process, total extracted RNA was quantitated
by ﬂuorimetry, and the RNA extraction yield was calculated.
2.3. DNase treatment and cDNA synthesis
For contaminant DNA removal, 1 g of total RNA was  treated
with 1 U of DNase I (Promega Corporation, Fitchburg, USA) and 1 U
of RNase inhibitor (Life Technologies, Carlsbad, USA) for 30 min
at 37 ◦C, followed by incubation with ethylene glycol tetraacetic
acid (EGTA) for 10 min  at 65 ◦C for DNase I inactivation. Each
600 ng sample of DNA-free RNA was  then reverse transcribed with
200 U M-MLV  (Life Technologies, Carlsbad, USA), 1 M reverse
speciﬁc primer SFV-R1 (5′-CTCAATGATGACGTGGAGCT), 0.5 mM
dNTPs, 0.1 M DTT, and RNase-free water. The reaction was  incu-
bated at 37 ◦C for 30 min, followed by enzyme inactivation at 70 ◦C
for 15 min. cDNA samples were stored at −20 ◦C until processed.
2.4. qPCR
qPCR runs were performed in a StepOneTM (Life Technologies,
Singapore) real-time ﬂuorescence detector thermocycler. The reac-
tion was  set-up using the Power SYBR® Green kit (Life Technologies,
Foster City, USA), 3 L cDNA sample, 50 nM forward primer SFV-S2
(5′-ACAGACTGTCACTGAGCAG), 50 nM reverse primer SFV-R2 (5′-
GTGACCATCTACTGCAGAGA) in 15 L total reaction volume. After
distribution of samples and standards, the optic plates (Life Tech-
nologies, Foster City, USA) were sealed and brieﬂy centrifuged
(1200 rpm for 3 min). qPCR was  performed at 95 ◦C for 10 min,
34 × (95 ◦C/15 s, 55 ◦C/15 s, 60 ◦C/15 s), and the ﬂuorescence was
measured at 60 ◦C. The threshold ﬂuorescence level for quantiﬁca-
tion was set within the exponential phase where all ampliﬁcation
curves exhibited the most signiﬁcant signal increase. The cycle
threshold (Ct) was obtained by recording the number of cycles
required for the ﬂuorescent signal to cross the threshold. After
ampliﬁcation, the melting curve (60–95 ◦C) was developed in order
to verify reaction speciﬁcity, with the ampliﬁed fragment (145 bp)
presenting dissociation at 83 ± 0.3 ◦C.
2.5. Standard curve
The standard curve for SFV-RNA quantitation was obtained by
serial dilution of pSFV-RVGP plasmid. pSFV-RVGP was produced
in bacteria, extracted, and puriﬁed using the Plasmid Maxi-Prep
kit (Qiagen, Maryland, USA). Plasmid was treated with DNase-free
RNase, quantitated by spectrophotometry and subsequently 2 g
of pSFV-RVGP was  linearized by Not I digestion and quantitated by
ﬂuorimetry using the Quant-itTM DNA assay kit (Life Technologies,
Carlsbad, USA). The concentration required for a speciﬁc num-
ber of the target sequence was calculated based on the mass of
a single plasmid molecule and the mass of plasmid containing the
copy number of interest. Six dilutions were performed in 10 mM
Tris + 1 mM EGTA buffer, generating the standard dilutions con-
taining 6 × 107, 6 × 106, 6 × 105, 6 × 104, 6 × 103 or 6 × 102 copies
in each 3 L. Four independent runs with three replicates of each
logical Methods 193 (2013) 647– 652 649
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Fig. 1. qRT-PCR standard curve for the titration of SFV. Four qRT-PCR standard curves
were obtained in parallel from six 10-fold dilutions of a reference DNA. Mean values
of  cycle tresholds (Ct) corresponding to each logarithm of standard copy numberA.L.P. Puglia et al. / Journal of Viro
tandard dilution were performed, and each standard curve was
eﬁned as the regression line of the logarithm of standard copy
umber versus Ct. A mean standard curve was  calculated from
revious curves and data was plotted. All curves were evaluated
n accordance with published guidelines (Nolan et al., 2006). Efﬁ-
iency was determined by the formula (Pfafﬂ, 2001)
 = 10(−1/S)
here “E” is efﬁciency and “S” is the slope of the standard curve.
.6. Titration of SFV RNA
cDNA obtained after reverse transcription of SFV RNA samples
ere ampliﬁed together with standard curve dilutions, in three
eplicates each. Mean Cts were applied to the standard curve equa-
ion to determinate the cDNA copy number in each sample. The
otal SFV RNA copy number present in the original SFV sample
as calculated by the multiplication of the cDNA copy number by
 conversion factor speciﬁc to each sample, which considered all
ilutions made and the yield of RNA extraction. Each SFV RNA copy
as considered to belong to one potentially infective particle, so
irus titer was expressed in virus particle per milliliter (VP/mL).
.7. Cell cultures and infection
BHK-21 cells were cultivated in -MEM medium (Life Technolo-
ies, Carlsbad, USA) containing 10% fetal calf serum (FCS), at 37 ◦C
nd 5% CO2. For infection studies, cells were seeded in six-well
lates at a concentration of 7 × 105 cells/well; the medium was
eplaced with -MEM containing the desired amount of recom-
inant SFV. The multiplicity of infection (MOI), or the amount of
FV/cell, was calculated based on the SFV titer and the cell number.
o provide a homogeneous infection and avoid temperature-
ediated degradation of viruses, the cultures were kept under
entle agitation at room temperature (24 ± 2 ◦C) for 2 h. The culture
edium was then replaced with 1.5 mL  of -MEM with FCS, and
ells were incubated at 37 ◦C. At different time points after infec-
ion, cells were resuspended in PBS + 5 mM EDTA by incubation at
7 ◦C for 5 min. Samples containing 3 × 105 cells were analyzed by
LISA (Perrin et al., 1996) for determination of RVGP production
ollowing previously published procedures of sample treatment
Astray et al., 2008; Benmaamar et al., 2009). For RVGP mRNA
uantitation, samples of 8 × 105 cells were RNA-extracted and the
rocedures of DNase treatment, reverse transcription, and qPCR
ere followed as previously described (Benmaamar et al., 2009).
.8. Flow cytometry analysis
To analyze the relationship between the MOI  used for infection
nd the relative amount of infected cells, three different lots of SFV-
FP were produced and titrated by qRT-PCR. Following titration,
irus lots were used for BHK-21 infection with MOI  1, 3, 5, 10, or
5. After 24 h cells were harvested with PBS + 5 mM EDTA, washed
nd ﬁxed with PBS + 0.2% para-formaldehyde. The proportions of
uorescent cells were determined by counting 10,000 events on a
ACSCaliburTM ﬂow cytometer (Becton Dickinson, San Jose, USA).
he equipment was calibrated with a mock infected BHK-21 as
egative control, and samples were read at wavelength of 530 nm.
.9. Fluorescence microscopyThe kinetics of GFP expression was evaluated by infecting BHK-
1 cells with SFV-GFP (MOI 10) and incubation at 37 ◦C in a MIU-IBS
O2 chamber coupled to an IX-81 ﬂuorescence microscope (Olym-
us, Tokyo, Japan). Photomicrographs were taken automaticallywere plotted. Equation of regression line shows the slope (−3.45) used for cal-
culation of ampliﬁcation efﬁciency as indicated above (1.91) and the correlation
coefﬁcient R2 (0.998). Error bars show SD.
from the same observation ﬁeld at several time points after infec-
tion using the OV100 in vivo imaging system (Olympus, Tokyo,
Japan).
2.10. Statistical analysis
The ANOVA test with a conﬁdence interval of 95% (p < 0.05) was
used for the RVGP and RVGP mRNA expression studies.
3. Results
The initial steps for standardizing the best conditions for anal-
ysis included the determination of the following parameters:
amount of sample for RNA extraction, DNase treatment efﬁcacy,
primer concentration, cDNA sample quantity, and qPCR ampliﬁca-
tion cycle. A qRT-PCR standard curve for SFV RNA titration was then
established after four ampliﬁcations to conﬁrm the reproducibil-
ity between different runs and to calculate the average efﬁciency
of ampliﬁcation (Fig. 1). The standard curve showed the basic
requirements necessary for qRT-PCR, namely, the use of at least
ﬁve dilutions of standard and a slope of standard curve preferably
between −3.3 and −3.8 and R2 value of 0.99. The reproducibility of
qRT-PCR was  accessed by the ampliﬁcation of a single cDNA sam-
ple obtained from an SFV pool, in nine replicates, in each one of
two independent PCR runs. The average standard deviations were
0.23 ± 0.06 Ct interassays and 0.10 ± 0.06 Ct intra-assays. These
data indicated that the standardized method was reproducible and
the assay suitable for analyzing the amount of SFV RNA in intended
samples. To prove that the proposed method actually applies to all
SFV constructs, three separate samples of each different SFV stock
(SFV-Mta-1, SFV-Ala-80, SFV-20A2, SFV-GFP, and SFV-RVGP) were
titered. All viruses were efﬁciently ampliﬁed, with an average accu-
mulated coefﬁcient of variation (CV) of 15.1% (i.e. for the whole
process of RNA extraction, DNase treatment, and qRT-PCR). Virus
titers ranged from 3.2 × 107 VP/mL to 8.3 × 108 VP/mL, a difference
of approximately 26 times between viral lots obtained by the same
molecular biology and transfection procedures (Table 1).
To demonstrate the correlation between the amount of viral
RNA used for cell infection and the amount of recombinant pro-
tein produced, BHK-21 cells were infected with different amounts
of a single lot of SFV-RVGP and then the mRNA accumulation
was measured; the RVGP produced is shown in Fig. 2A and B
shows the cell growth kinetics. Infections at MOIs of 0.15, 1.5 or
15 SFV RNA/cell produced similar proﬁles of RVGP mRNA expo-
nential accumulation into cells, leading to maximum quantities
statistically different between 12 h and 24 h. RVGP accumulation
was proportional to RVGP mRNA levels and reached the highest
650 A.L.P. Puglia et al. / Journal of Virological Methods 193 (2013) 647– 652
Table  1
qRT-PCR titration of different recombinant SFV.
Virus Viral titer (VP/mL) Standard deviation CV (%)
SFV-Mta-1 6.31 × 108 5.6 × 107 9.0
SFV-Ala-80 8.20 × 108 1.4 × 108 17.6
SFV-20A2 0.32 × 108 6.2 × 106 19.3
SFV-GFP 1.45 × 108 2.2 × 107 15.2
SFV-RVGP 8.30 × 108 1.2 × 108 14.4
SFV-RVGP, rabies virus glycoprotein; SFV-GFP, green ﬂuorescent protein; SFV-Mta-
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Table 2
Effect of temperature treatment on SFV-RVGP inactivation. SFV-RVGP titration by
qRT-PCR, and RVGP synthesis in infected BHK-21 cells.
SFV-RVGP inactivation SFV-RVGP infection
Incubation Titer (VP/mL) Titer decrease (%) RVGP (ng/mL)
24 ◦C/1 h 8.12 × 108 2.2 265.3 ± 25.1
24 ◦C/3 h 7.66 × 108 7.7 260.8 ± 14.6
37 ◦C/1 h 3.61 × 108 56.5 241.3 ± 22.2
37 ◦C/3 h 1.45 × 108 82.5 244.4 ± 15.9
−20 ◦C (stock) 8.30 × 108 – 302.1 ± 9.6
Identical SFV-RVGP samples were incubated at different temperatures for different
times and then submitted to qRT-PCR titration, and used for BHK-21 infection (MOI,  melatonin A1 receptor; SFV-Ala-80, modiﬁed adenosine receptor and SFV-20A2,
denosine receptor A2A. CV, coefﬁcient of variation. Data represent the mean value
f three independent assays.
oncentrations at 30 h post-infection. After 30 h the amounts of
ranscript and RVGP decreased, mainly in cells infected with MOI  15
Fig. 2A). At this time, viable cell concentration started to increase
ue to the multiplication of uninfected cells (Fig. 2B). These data
lso showed that when less than MOI  15 was used for infec-
ion, many cells were not infected and continued to divide, which
as evident mainly after 24 h post-infection. Surprisingly, a large
umber of BHK-21 cells infected with an MOI  0.15 showed high
ytotoxicity despite low RVGP expression levels, reaching 24 h of
nfection with only 59.7% of initial culture viability, while the cul-
ures infected with MOI  1.5 and 15 presented viabilities of 51.8%
nd 29.7%, respectively.In order to show further the correlation of qRT-PCR titrated virus
nput and the amount of RVGP produced in infected cells, aliquots
f a single lot of SFV-RVGP were subjected to different tempera-
ure treatments and then qRT-PCR titrated in ﬁve replicates (mean
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ig. 2. Kinetics of RVGP mRNA copy number, RVGP expression, and growth in cul-
ures of BHK-21 infected with different MOI  (0.15, 1.5, and 15) of SFV-RVGP. RVGP
RNA was determined by qRT-PCR in 90 ng of total RNA and expressed in Log10 copy
umber; RVGP was  determined by ELISA and expressed as g of RVGP/107 cells (A);
iable cell concentration was  determined by cell counting in a hemocytometer by a
rypan exclusion method. X, cells/mL × 105 (2B). *Statistically different from other
alues (p < 0.05).10)  in three replicates. Virus inactivation is expressed in % related to the viral stock
at  −20 ◦C. RVGP synthesis in the different groups (n = 3) was  measured by ELISA and
was  considered statistically equivalent (p = 0.015).
CV = 15%). Subsequently, temperature-treated virus aliquots were
used for infection of BHK-21 cells at MOI  10, and RVGP production
was measured (Table 2). The results show that the incubation of
virus suspensions at temperatures of 25 ◦C or 37 ◦C, for 1 h or 3 h,
led to the partial SFV RNA degradation since virus titers decreased
as compared to virus stock maintained at −20 ◦C. The treatment
at 37 ◦C for 3 h, especially, resulted in a signiﬁcant loss of viral
titer (82.4%). In comparing RVGP production among the cultures
infected with an MOI  10 of the temperature-treated SFV particles,
results were very similar (standard deviation [SD] = 11.87 ng/mL;
CV = 4.69%), demonstrating a correlation between the amount of
SFV RNA used for infection and the RVGP expression, which rein-
forces the applicability of qRT-PCR for titration of SFV constructs.
Cultures infected with SFV stocked at −20 ◦C presented RVGP values
14–20% higher than temperature-treated cultures, raising variation
values (SD = 24.26 ng/mL; CV = 9.23%).
Finally, the qRT-PCR method was  used for the titration of differ-
ent lots of SFV-GFP, which were used to infect BHK-21 cells with
different MOIs. Infected cells expressed the GFP and were analyzed
by ﬂuorescence microscopy or ﬂow cytometry (Fig. 3). Fluorescence
microscopy analysis was used for deﬁning the best time after infec-
tion for measuring the amount of infected cells in a kinetic study
of GFP expression after BHK-21 infection with SFV-GFP with MOI
10 (Fig. 3A). Photomicrographs show the ﬁrst signs of GPF expres-
sion at 1 h of infection. Increased amounts of ﬂuorescent cells were
observed until 24 h of infection, so this time point was chosen
for analysis of GFP expression after infecting cells with different
MOIs (Fig. 3B). The results show that an increase in the MOI  corre-
sponded to an increase, although not proportionally, in the percent
of infected cells. Most importantly, when three different SFV-GFP
lots were used with the same MOIs, similar amounts of cells were
shown to express GFP, as indicated by the low SD observed in the
assays. From the equation on the data graph, the predicted MOI for
attaining 100% of infected cells would be 22.9.
4. Discussion
The SFV expression system has been used widely for recom-
binant protein expression in mammalian cells, markedly for
membrane proteins (Lundstrom, 2003; Hassaine et al., 2006). This
system is also a promising vector for studies of immunization,
cancer therapy (Riezebos-Brilman et al., 2006), and for neuro-
science investigations (Lundstrom et al., 2001). The application of
an qRT-PCR method for easy and reliable recombinant SFV titra-
tion is suggested. First, a standard curve was established based
on the linearized SFV expression plasmid, and its characteristics
were evaluated, which corresponded to the basic requirements
needed to validate the qRT-PCR (Nolan et al., 2006). The ampliﬁ-
cation of different SFV constructs conﬁrmed that the standardized
method is applicable to any SFV with a conserved nsp1 gene in the
A.L.P. Puglia et al. / Journal of Virological Methods 193 (2013) 647– 652 651
Fig. 3. Correlation between MOI  and infection of BHK-21 cells with SFV-GFP. Microphotographs of the same observation ﬁeld were taken at several time points for the study
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sed  for BHK-21 infection with different MOI  for 24 h. Amounts of ﬂuorescent cells
D.  Fluorescence CV were 5.7%, 7.5%, 9.6%, 13.1%, and 11.4%, for MOIs 1, 3, 5, 10, and
on-structural polyprotein region. Furthermore, the large differ-
nce in viral titers between these constructions showed that even
f the same steps are followed for producing recombinant SFV par-
icles, a broad range of viral titers can be obtained after completion
f all processes of molecular biology, transfection, cultivation of
ells, and virus harvesting. The qRT-PCR method is able to deter-
ine the virus titer on the interval between 600 and 60 million
opies of SFV RNA per sample, in one reaction in a few hours.
his is an advantage if compared to quantitation by immunoﬂuo-
escence, which is not sensitive enough and requires performing
everal virus dilutions, cell cultivation, antibody labeling, and a
ew days to complete. In addition, large stocks of SFV, even stored
nder the best conditions, are subjected to potency loss due to
he labile nature of RNA. When different aliquots of the same
atch of SFV-RVGP were treated at different temperatures to pro-
ote partial degradation of the SFV RNA, the standardized qRT-PCR
itration method was able to measure with accuracy the extent
f degradation. When the temperature-treated viruses were used
or BHK-21 infection with the same MOI, very similar amounts of
VGP were produced, demonstrating that there was a good corre-
ation between the amount of SFV-containing preserved RNA used
or infection and the RVGP expression. The difference between
he amounts of RVGP produced by cultures infected with freezer
tock SFV-RVGP and temperature-treated stock, although noted cells increased until 24 h after infection (400×) (A). Three lots of SFV-GFP were
determined by ﬂow cytometry. Data show mean ﬂuorescence (). Error bars show
espectively (B).
statistically signiﬁcant, may  represent the effect of virus degrada-
tion due to an additional freeze-thaw step of SFV particles which
were frozen after temperature treatment while qRT-PCR titration
was performed. Therefore, it is important to have aliquots of an
SFV stock available for titration, as repeated freeze–thaw cycles
can interfere with the determination of the correct virus titer and
MOI. Taking this into consideration, virus samples may  be titrated
accurately before use, allowing a precise and reliable calculation of
the amount of SFV particles under optimal conditions. This ﬁnding
is important because it demonstrates that the degradation of a viral
batch can be measured effectively. It is different from the titration
of DNA virus vectors, whose degradation sometimes are not appar-
ent by qPCR analysis because DNA is more stable than RNA and
can remain in suspension, resulting in overestimation of viral titer
(Hitchman et al., 2007).
The reproducibility of this method was evaluated by assays
using SFV-GFP. Three different SFV-GFP batches were titrated by
qRT-PCR, showing very different amounts of SFV RNA. When they
were used for infecting cells with the same MOI, the rates of
ﬂuorescent cells were very similar. Therefore, with the qRT-PCR
titration approach, the titer variability between SFV batches can
be well-identiﬁed by evaluating the number of active virus parti-
cles. qRT-PCR virus titers can then be accurately used to calculate
the virus input based on the desired MOI, obtaining reproducible
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esults. Finally, when an SFV-RVGP batch was titrated based on the
FV RNA content and then used for infection in three log different
OIs, the amount of virus used was shown to be proportional to
he amount of RVGP mRNA produced by cells, and consequently,
roportional to RVGP production.
. Conclusion
In conclusion, SFV titers determined by qRT-PCR can be accu-
ately used to calculate the virus input based on the desired MOI,
btaining reproducible results. Also, qRT-PCR methods targeting
iral RNA of non-structural proteins, as the method established
ere, can be accurate and reliable tools for the titration of any
eplication-defective viral vector.
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